Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Go back to Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 228.41 +0.81 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $225.87 | 52 Week Low | $223.02 | |||
| Day High | $230.49 | P/E | 29.25 | |||
| Day Low | $225.51 | EPS | $7.81 | |||
| Volume | 599,036 | |||||
